ClinicalTrials.gg
CompletedNCT05376150X-NOVAUpdated Sep 21, 2026Results posted

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

A Phase 2 interventional study of XEN1101 10 mg and XEN1101 20 mg in Major Depressive Disorder, sponsored by Xenon Pharmaceuticals Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
410th of 1,323
168 · median 70
Started
2022
with 51 others
Phase 2
271 of 1,500
45 open now
Registered
1,181st of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 410th largest by enrollment of the 1,323 interventional ones that give a count, is one of 52 that started in 2022, is one of 271 in phase 2, and was the 1,181st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

Read the detailed description

The study is divided into 3 stages: Screening - up to 4 weeks duration; Treatment - 6 weeks duration; Follow-up - 4 weeks duration. The total study duration per subject is estimated to be approximately 14 weeks.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Potassium channel
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Be properly informed of the nature and risks of the study and given written .
  • Male or female, aged 18 through 65 years (inclusive) with a (BMI) ≤35 kg/m².
  • Subject must meet the , Fifth Edition (DSM-5) criteria for current MDD and currently in a moderate to severe major depressive episode (MDE), confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • Current MDE duration ≥2 months and \<24 months at the time of screening.
  • Current illness severity that is at least moderate, defined as a score of ≥20 on the HAM-D17 at screening and on Day 1.
  • Score ≥20 on the SHAPS at screening and on Day1.
  • Must be willing to comply with the study protocol for the full term of the study.

Key Exclusion Criteria:

  • A primary psychiatric diagnosis other than MDD as defined by DSM-5 (comorbid anxiety disorders [including agoraphobia, generalized anxiety disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and panic disorder] are allowed).
  • Concomitant use of antidepressants and/or other disallowed pharmacotherapy (including benzodiazepines).
  • History of schizophrenia or other psychotic disorder, MDD with psychotic features, bipolar I or II disorder, or MDD with mixed features.
  • History of non-response to >1 antidepressant drug due to lack of efficacy in the current MDE.
  • Failing >3 antidepressant drug trials, for any reason, in the current MDE.
  • History of non-response to electroconvulsive therapy (ECT) in the past 10 years.
  • Active suicidal plan/intent in the past 6 months, or more than 1 lifetime suicide attempt.
  • Females who are pregnant, breastfeeding, or planning to become pregnant during the first administration of study drug until 3 months after the last dose of study drug.
  • Meets criteria for a substance use disorder within the past 12 months, with the exception of tobacco use, and/or has a positive urine toxicology screen for drugs of abuse.
  • Any medical condition or personal circumstance that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study or prevents adherence to the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    XEN1101 10 mg

    During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day

    Drug: XEN1101 10 mg

  • Experimental
    XEN1101 20 mg

    During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day

    Drug: XEN1101 20 mg

  • Placebo comparator
    placebo

    During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated, 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 (normal/absent) to 6 (severe), yielding a total score ranging from 0 to 60, with higher scores indicating greater depression severity. MADRS total score change from baseline at week 6.

    Time frame: From baseline to end of treatment (Week 6).

Secondary outcomes

  1. Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score.

    Snaith-Hamilton Pleasure Scale (SHAPS) is a validated 14-item self-report questionnaire commonly used to assess anhedonia (reduced ability to experience pleasure). Each of the 14 items is rated from 1 (strongly agree) to 4 (strongly disagree). Total scores range from 14 to 56, with higher scores indicating greater levels of anhedonia. SHAPS total score change from baseline at week 6

    Time frame: From baseline to end of treatment (Week 6).

  2. Change in Beck Anxiety Inventory (BAI) Score.

    Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms. Each item is scored on a scale from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. BAI total score change from baseline at week 6

    Time frame: From baseline to end of treatment (Week 6).

07

Results

Posted Sep 21, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mg
Started565656
Safety population555656
Modified intent-to-treat (mitt) population545555
Completed475046
Not completed9610

Outcome measures

PrimaryChange in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.

Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated, 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 (normal/absent) to 6 (severe), yielding a total score ranging from 0 to 60, with higher scores indicating greater depression severity. MADRS total score change from baseline at week 6.

Time frame:
From baseline to end of treatment (Week 6).
Reported as:
Least squares mean · MADRS total score
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.
MADRS total scorePlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mg
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.-13.90 ± 1.41-15.61 ± 1.34-16.94 ± 1.45
SecondaryChange in Snaith-Hamilton Pleasure Scale (SHAPS) Score.

Snaith-Hamilton Pleasure Scale (SHAPS) is a validated 14-item self-report questionnaire commonly used to assess anhedonia (reduced ability to experience pleasure). Each of the 14 items is rated from 1 (strongly agree) to 4 (strongly disagree). Total scores range from 14 to 56, with higher scores indicating greater levels of anhedonia. SHAPS total score change from baseline at week 6

Time frame:
From baseline to end of treatment (Week 6).
Reported as:
Least squares mean · Change in SHAPS total score
Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score.
Change in SHAPS total scorePlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mg
Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score.-5.30 ± 0.85-6.71 ± 0.81-7.77 ± 0.87
SecondaryChange in Beck Anxiety Inventory (BAI) Score.

Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms. Each item is scored on a scale from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. BAI total score change from baseline at week 6

Time frame:
From baseline to end of treatment (Week 6).
Reported as:
Least squares mean · Change in BAI total score
Change in Beck Anxiety Inventory (BAI) Score.
Change in BAI total scorePlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mg
Change in Beck Anxiety Inventory (BAI) Score.-6.27 ± 0.91-7.27 ± 0.86-6.94 ± 0.94

Adverse events

Collected over 10 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/55 (0%)2/55 (3.6%)15/55 (27.3%)
Azetukalner (XEN1101) 10 mg0/56 (0%)0/56 (0%)18/56 (32.1%)
Azetukalner (XEN1101) 20 mg0/56 (0%)0/56 (0%)31/56 (55.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mg
Idiopathic intracranial hypertensionNervous system disorders1/550/560/56
Homicidal ideationPsychiatric disorders1/550/560/56
Most frequent other events
Most frequent other events
EventPlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mg
DizzinessNervous system disorders4/554/5610/56
HeadacheNervous system disorders7/555/565/56
SomnolenceNervous system disorders1/556/566/56
Disturbance in attentionNervous system disorders0/550/565/56
DepressionPsychiatric disorders2/553/562/56
ParaesthesiaNervous system disorders1/550/563/56

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
Mean47.5 ± 12.747.4 ± 14.646.6 ± 13.847.2 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
Female374430111
Male18122656
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
Asian1225
Black or African American16222058
White or Caucasian373232101
Multiracial1023
Region of Enrollment
Region of Enrollment(participants)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
United States555656167
MADRS total score at baseline
MADRS total score at baseline(MADRS baseline score)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
Mean34.5 ± 4.634.2 ± 4.833.1 ± 5.833.9 ± 5.1
SHAPS total score at baseline
SHAPS total score at baseline(SHAPS baseline score)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
Mean35.3 ± 5.636.8 ± 5.437.5 ± 6.336.5 ± 5.8
BAI total score at baseline
BAI total score at baseline(BAI baseline score)PlaceboAzetukalner (XEN1101) 10 mgAzetukalner (XEN1101) 20 mgTotal
Mean13.5 ± 8.312.5 ± 9.114.9 ± 13.613.6 ± 10.6
08

Study locations

20 sites
  • Advanced Research Center
    Anaheim, California 92805, United States
  • Sunwise Clinical Research, LLC
    Lafayette, California 94549, United States
  • California Neuropsychopharmacology Clinical Research Institute
    Pico Rivera, California 90660, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Meridian International Research
    Miami, Florida 33014, United States
  • Global Medical Institutes (GMI)
    Miami, Florida 33125, United States
  • CCM Clinical Reseach Group, LLC
    Miami, Florida 33133, United States
  • i-Research, Atlanta
    Decatur, Georgia 30030, United States
  • Psych Atlanta, PC
    Marietta, Georgia 30060, United States
  • iResearch
    Savannah, Georgia 31405, United States
  • Revive Research Institute, Inc.
    Elgin, Illinois 60123, United States
  • Altea Research
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Marlton, New Jersey 08009, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Neurobehavioral Research, Inc. (NBR)
    Cedarhurst, New York 11516, United States
  • Manhattan Behavioral Medicine, PLLC
    New York, New York 10036, United States
  • Richard M Weisler and Association
    Raleigh, North Carolina 27609, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • AIM Trials
    Plano, Texas 75093, United States
09

References and documents

Publications

  • Butterfield NN, Luzon Rosenblut C, Fava M, Correll CU, Rothschild AJ, Murrough JW, Mathew SJ, Beatch GN, Grayson C, Harden C, Qian J, McIntosh J, Namdari R, Kenney C. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 1;8(5):e2514278. doi: 10.1001/jamanetworkopen.2025.14278. PubMed 40423966 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2023, 15 months.

Results were first posted in Sep 2026, 3 years after primary completion. A results delay was requested in Sep 2024.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 15 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2022
First posted
May 17, 2022
StartActual
May 19, 2022
Primary completionActual
Sep 18, 2023
CompletionActual
Oct 16, 2023
Results delay requested
Sep 13, 2024
Results first posted
Sep 21, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05376150
Responsible party
Sponsor
First posted
May 17, 2022
Start date
May 19, 2022
Primary completion
Sep 18, 2023
Completion
Oct 16, 2023
Results posted
Sep 21, 2026
Last update
Sep 21, 2026

Study contacts

Study Director
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion